BackZenas BioPharma Overview

Zenas BioPharma Net Tangible Assets

Zenas BioPharma's net tangible assets is $340M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$335.83M

Peer average

Loading

Zenas BioPharma Net Tangible Assets History

Loading

Zenas BioPharma vs. peers: Net Tangible Assets Comparison

Loading

Zenas BioPharma Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zenas BioPharma (ZBIO) FAQ

As of the most recent data (March 2026), ZBIO shows a net tangible assets of $340M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZBIO's net tangible assets is now $340M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Zenas BioPharma is outperforming or lagging.

Tracking ZBIO's net tangible assets over time shows whether Zenas BioPharma is scaling, shrinking, or reshaping that part of the business. The current reading is $340M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Zenas BioPharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $340M) with ownership activity and broader fundamentals.

Zenas BioPharma's net tangible assets is $340M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.